Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.

Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. J Med Chem. 2020 07 09; 63(13):7186-7210.

View in: PubMed

subject areas

Animals
Breast Neoplasms
Drug Resistance, Neoplasm
Humans
MCF-7 Cells
Mice
Models, Molecular
Piperazines
Protein Domains
Pyridines
Pyridones
Receptors, Estrogen
Tissue Distribution
Transcription Factors
Xenograft Model Antitumor Assays

authors with profiles

Jiong Zhao